Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Pharmaceutical Statistics|April 1, 2018
Better decision making in drug development through adoption of formal prior elicitationNigel Dallow, Nicky Best, Timothy H Montague
The AAPS Journal|June 12, 2012
Re-introduction of a novel approach to the use of stable isotopes in pharmacokinetic studiesAlan Parr, Manish Gupta, Timothy H Montague, et al.
Pharmacoepidemiology and Drug Safety|December 19, 2017
Assessing a composite end point for new tocolytics in clinical trials: Data from 4 US integrated delivery networksJeanne M Pimenta, Emma Brinkley, Timothy H Montague, et al.
Pharmaceutical Statistics|February 11, 2011
Additional results for 'Sequential design approaches for bioequivalence studies with crossover designs'Timothy H Montague, Diane Potvin, Charles E Diliberti, et al.
Pharmaceutical Statistics|November 6, 2015
Optimal adaptive sequential designs for crossover bioequivalence studiesJialin Xu, Charles Audet, Charles E DiLiberti, et al.
British Journal of Clinical Pharmacology|March 31, 2015
Treatment of spontaneous preterm labour with retosiban: a phase 2 proof-of-concept studySteven Thornton, Hugh Miller, Guillermo Valenzuela, et al.
AJP Reports|March 13, 2018
A Retrospective Database Analysis of Neonatal Morbidities to Evaluate a Composite Endpoint for Use in Preterm Labor Clinical TrialsJeanne M Pimenta, Myla Ebeling, Timothy H Montague, et al.
British Journal of Clinical Pharmacology|May 31, 2017
Treatment of spontaneous preterm labour with retosiban: a phase II pilot dose-ranging studySteven Thornton, Guillermo Valenzuela, Charlotte Baidoo, et al.
The American Journal of Cardiology|May 29, 2004
Evaluation of vardenafil and sildenafil on cardiac repolarizationJoel Morganroth, Bernard E Ilson, Bonnie C Shaddinger, et al.
American Journal of Perinatology|May 8, 2020
Randomized Trials of Retosiban Versus Placebo or Atosiban in Spontaneous Preterm LaborGeorge R Saade, Andrew Shennan, Kathleen J Beach, et al.
Pageof 1